These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26685489)

  • 41. [Medicines raw materials used in compounding medicines: an update of the legislation].
    Huyghebaert C; Leuckx S
    J Pharm Belg; 2010 Mar; (1):16-8. PubMed ID: 20429391
    [No Abstract]   [Full Text] [Related]  

  • 42. GMPs vs GCPs: United States Pharmacopeia General Chapters.
    Allen LV
    Int J Pharm Compd; 2013; 17(5):439. PubMed ID: 24459791
    [No Abstract]   [Full Text] [Related]  

  • 43. A compounding compliance team at an academic medical center.
    Chaffee BW; Tharp JC; Clark JS; Kent S
    Am J Health Syst Pharm; 2020 May; 77(11):882-891. PubMed ID: 32318700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Change Is In the Air: What You Need to Know About Pharmacy Ventilation Under United States Pharmacopeia <800>.
    Laniewicz C
    Int J Pharm Compd; 2017; 21(4):271-274. PubMed ID: 28719368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. End-preparation assessments and tests for compounded sterile preparations.
    McElhiney LF
    Int J Pharm Compd; 2013; 17(4):307-11. PubMed ID: 24261146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy.
    Sunenshine RH; Tan ET; Terashita DM; Jensen BJ; Kacica MA; Sickbert-Bennett EE; Noble-Wang JA; Palmieri MJ; Bopp DJ; Jernigan DB; Kazakova S; Bresnitz EA; Tan CG; McDonald LC
    Clin Infect Dis; 2007 Sep; 45(5):527-33. PubMed ID: 17682984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toward Better-Quality Compounded Drugs - An Update from the FDA.
    Woodcock J; Dohm J
    N Engl J Med; 2017 Dec; 377(26):2509-2512. PubMed ID: 29281577
    [No Abstract]   [Full Text] [Related]  

  • 48. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract]   [Full Text] [Related]  

  • 49. Quality Assurance and Quality Control, Part 1.
    Akers MJ
    Int J Pharm Compd; 2015; 19(2):121-4. PubMed ID: 26685493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Revisions continue on USP sterile-compounding chapter.
    Thompson CA
    Am J Health Syst Pharm; 2005 Sep; 62(18):1856, 1858, 1861-2. PubMed ID: 16141100
    [No Abstract]   [Full Text] [Related]  

  • 51. Contemporary pharmaceutical compounding.
    Allen LV
    Ann Pharmacother; 2003 Oct; 37(10):1526-8. PubMed ID: 14519042
    [No Abstract]   [Full Text] [Related]  

  • 52. Application of standards for compounding.
    Newton DW
    J Am Vet Med Assoc; 1994 Jul; 205(2):232-4. PubMed ID: 7928584
    [No Abstract]   [Full Text] [Related]  

  • 53. Sterilization of compounded parenteral preparations: verification of autoclaves.
    Rahe H
    Int J Pharm Compd; 2013; 17(2):94-8. PubMed ID: 23696169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Basics of compounding: considerations for implementing United States pharmacopeia chapter 797 pharmaceutical compounding-sterile preparations, part 4: considerations in selection and use of disinfectants and antiseptics.
    Allen LV; Okeke CC
    Int J Pharm Compd; 2007; 11(6):492-9. PubMed ID: 23994811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The future of USP monographs for PET drugs.
    Schwarz S; Norenberg J; Berridge M; Dragotakes S; Hung J; Link J; Mason NS; Mattmuller S; Nickel RA; Packard A; Paolino J; Petry N; Ponto J; Quinton TM; Seifert KL; Swanson D; Weiner RE; Zigler S
    J Nucl Med; 2013 Mar; 54(3):472-5. PubMed ID: 23264689
    [No Abstract]   [Full Text] [Related]  

  • 56. Joint Commission expectations related to USP-NF Chapter 797 on compounding sterile preparations.
    Jt Comm Perspect; 2006 Apr; 26(4):5. PubMed ID: 16786622
    [No Abstract]   [Full Text] [Related]  

  • 57. Multistate fungal meningitis outbreak -- interim guidance for treatment.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(41):842. PubMed ID: 23076094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The potential impact of USP 797 and what the JCAAI is doing about it.
    Nathan R
    Allergy Asthma Proc; 2007; 28(2):236-7. PubMed ID: 17479611
    [No Abstract]   [Full Text] [Related]  

  • 59. Basics of Sterile Compounding: Criteria for Determining Beyond-use Dating.
    Martin M
    Int J Pharm Compd; 2018; 22(4):303-312. PubMed ID: 30021186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prepare now for USP standard on handling hazardous drugs.
    Traynor K
    Am J Health Syst Pharm; 2015 Apr; 72(7):511-2, 514. PubMed ID: 25788501
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.